MendesRE, CastanheiraM, FarrellDJ, et al.Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency. J Antimicrob Chemother, 2016; 71:3453–3458.
2.
LeeT, PangS, AbrahamS, CoombsGW. Antimicrobial resistant CC17 Enterococcus faecium: The past, the present and the future. J Glob Antimicrob Resist, 2019; 16:36–47.
3.
BabarN, UsmanJ, MunirT, et al.Frequency and antibiogram of vancomycin resistant enterococcus in a tertiary care hospital. J Coll Physicians Surg Pak, 2014; 24:27–29.
4.
DomingoM-C, HuletskyA, GirouxR, et al.High prevalence of glycopeptide resistance genes vanB, vanD, and vanG not associated with enterococci in human fecal flora. Antimicrob Agents Chemother, 2005; 49:4784–4786.
